Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2022
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,491
-3.44%
|
$89,460
$60.27 P/Share
|
|
Mar 03
2022
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,719
-1.83%
|
$103,140
$60.27 P/Share
|
|
Mar 03
2022
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,328
-3.21%
|
$79,680
$60.27 P/Share
|
|
Mar 03
2022
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,667
-3.63%
|
$100,020
$60.28 P/Share
|
|
Mar 03
2022
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
1,066
-4.2%
|
$63,960
$60.27 P/Share
|
|
Mar 03
2022
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,197
-2.56%
|
$71,820
$60.28 P/Share
|
|
Mar 03
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
7,862
-4.01%
|
$471,720
$60.28 P/Share
|
|
Mar 03
2022
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
761
-5.87%
|
$45,660
$60.27 P/Share
|
|
Mar 03
2022
|
Mark Alan Goldberg Director |
BUY
Open market or private purchase
|
Direct |
5,000
+31.62%
|
$295,000
$59.98 P/Share
|
|
Mar 01
2022
|
Jeffrey W. Albers Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+3.69%
|
-
|
|
Mar 01
2022
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+20.74%
|
-
|
|
Mar 01
2022
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+20.38%
|
-
|
|
Mar 01
2022
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+21.39%
|
-
|
|
Mar 01
2022
|
Michael Landsittel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+23.19%
|
-
|
|
Mar 01
2022
|
L. Becker Hewes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+20.03%
|
-
|
|
Mar 01
2022
|
Kate Haviland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+29.86%
|
-
|
|
Mar 01
2022
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+22.24%
|
-
|
|
Mar 01
2022
|
Christina Rossi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+24.3%
|
-
|
|
Mar 01
2022
|
Debra Durso Bumpus Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+22.37%
|
-
|
|
Mar 01
2022
|
Ariel Hurley Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+18.14%
|
-
|
|
Dec 15
2021
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$72,900
$100.0 P/Share
|
|
Dec 15
2021
|
L. Becker Hewes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Dec 13
2021
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.46%
|
$98,000
$98.13 P/Share
|
|
Dec 13
2021
|
Kate Haviland Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Dec 08
2021
|
Tango Therapeutics, Inc. Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+50.0%
|
-
|
|
Dec 07
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.41%
|
$480,000
$96.46 P/Share
|
|
Dec 07
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.51%
|
$140,000
$28.36 P/Share
|
|
Nov 16
2021
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,950
-16.19%
|
$222,300
$114.28 P/Share
|
|
Nov 16
2021
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,950
+5.4%
|
$15,600
$8.56 P/Share
|
|
Nov 15
2021
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$83,835
$115.49 P/Share
|
|
Nov 15
2021
|
L. Becker Hewes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Nov 15
2021
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
30,000
-3.54%
|
$3,390,000
$113.51 P/Share
|
|
Nov 15
2021
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.51%
|
$240,000
$8.44 P/Share
|
|
Nov 03
2021
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
511
-1.15%
|
$56,210
$110.85 P/Share
|
|
Nov 03
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.66%
|
$550,000
$110.18 P/Share
|
|
Nov 03
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$140,000
$28.36 P/Share
|
|
Nov 01
2021
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.58%
|
$575,000
$115.16 P/Share
|
|
Nov 01
2021
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.52%
|
$75,000
$15.01 P/Share
|
|
Nov 01
2021
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,177
-5.04%
|
$579,824
$112.91 P/Share
|
|
Nov 01
2021
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,177
+6.91%
|
$139,779
$27.03 P/Share
|
|
Oct 15
2021
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
729
-2.71%
|
$74,358
$102.66 P/Share
|
|
Oct 15
2021
|
L. Becker Hewes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+2.64%
|
$48,114
$66.24 P/Share
|
|
Oct 05
2021
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
3,241
-7.11%
|
$317,618
$98.18 P/Share
|
|
Sep 23
2021
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
848
-2.67%
|
$93,280
$110.01 P/Share
|
|
Sep 23
2021
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
848
+2.6%
|
$30,528
$36.05 P/Share
|
|
Sep 23
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
25,000
-16.2%
|
$2,700,000
$108.78 P/Share
|
|
Sep 23
2021
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+30.02%
|
$700,000
$28.36 P/Share
|
|
Sep 23
2021
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
600
-5.61%
|
$66,000
$110.0 P/Share
|
|
Sep 23
2021
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.31%
|
$9,000
$15.01 P/Share
|
|
Sep 15
2021
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,833
-8.7%
|
$1,183,300
$100.52 P/Share
|